Harbinger Health, a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection, announced today the appointment of Dymeka Harrison as Chief Commercial Officer (CCO), Mathew Sargent as Chief Business Officer (CBO), and Gisela Paulsen as Chief Operating Officer (COO), positioning the Company for continued growth and platform and product advancement.
Mses. Harrison and Paulsen and Mr. Sargent join Harbinger’s existing executive team, which includes Stephen Hahn, M.D., CEO; Vincent Lozada, CFO; May Orfali, M.D., CMO; Tony Shuber, Chief Innovation Officer; Kieran Chacko, Head of Data Science and Strategy; David Lambe, SVP, Portfolio Strategy and Operations; and Leila Gjika, VP, Head of Human Resources.
“Harbinger is laser-focused on our mission to create a new cancer screening paradigm by delivering accessible and low-cost early-stage screening tools,” said Dr. Hahn. “Dymeka, Matt and Gisela strengthen our leadership team, expanding our collective expertise across diagnostics, commercialization, biotechnology finance, and data science as we advance our product platform and prepare to launch our first products in 2025.”
Dymeka Harrison joined as Chief Commercial Officer with over 20 years of experience in the diagnostics industry. In her newly appointed role, Ms. Harrison will oversee the execution of Harbinger’s commercial strategy and launch of Harbinger’s suite of cancer detection products. She most recently served as Chief Commercial Officer at Foundation Medicine, where she led global clinical and commercial strategies for all product lines. Previously, she was Head of Strategic Marketing at Abbott Laboratories’ Rapid Diagnostics Division, overseeing global marketing efforts. Ms. Harrison earned an Executive Master of Business Administration degree from Georgia State University, as well as a Bachelor of Science in both Manufacturing Engineering as well as Computer Technology and Electronics Engineering from North Carolina A&T State University.
